PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)

NCT03255915 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

15

Enrollment

OTHER

Sponsor class

Conditions

HIV Prevention

Interventions

DRUG: Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)
OTHER: Placebo

Sponsor

Oak Crest Institute of Science

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]